FDA Rewrites Its Rulebook to Make Room Beyond Animal Tests

FDA has paired a direct final rule with a companion proposal to replace animal-centered language across its human drug and biologic regulations with the broader term “nonclinical.” The change is narrow—FDA says it adds no requirements and is not expected to alter industry practice—but it matters because regulatory vocabulary can either welcome newer testing methods or leave them standing awkwardly outside the door.

What It Is

The two documents, published September 22 under docket FDA-2026-N-5347 and RIN 0910-AJ27, implement terminology Congress adopted in the 2022 Food and Drug Omnibus Reform Act. That law defined a nonclinical test broadly enough to include cell-based assays, organ chips and microphysiological systems, computer modeling, bioprinting, and animal studies. FDA is now carrying that approach into regulations governing investigational drugs, marketing applications, biologics, safety reporting, and related requirements.

What’s Changing

The direct final rule replaces references to “animal,” “preclinical,” and, in selected provisions, “in vitro” tests or studies with “nonclinical” terminology. It also adds definitions covering tests conducted in vitro, in silico, in chemico, or in nonhuman animals. FDA stresses that sponsors already submit data from these methods when appropriate; the rule clarifies that the regulations do not make animal testing the only route and does not expand what must be reviewed, submitted, or reported.

The procedural setup comes with a small Washington booby trap. Comments are due December 7, 2026. If FDA receives no significant adverse comments, it plans to confirm the direct final rule’s February 4, 2027 effective date. If significant adverse comments arrive, FDA intends to withdraw that rule and use the companion proposal to continue through ordinary notice-and-comment rulemaking.

Why It Matters

For drug and biologic developers, the immediate effect is permission made explicit rather than a new mandate. The text gives clearer regulatory footing to scientifically valid new approach methodologies while preserving animal studies as an available option. FDA estimates no annualized net cost savings and says the amendments impose no new requirements, so this is not an overnight rewrite of development programs.

The longer-term signal is more interesting. Definitions influence which evidence strategies sponsors are willing to invest in, discuss with FDA, and build into safety programs. Clearer recognition of organ chips, computational models, and other human-biology-based methods could support gradual changes in preclinical development when those tools are fit for purpose—without pretending that every animal study has suddenly become obsolete.

In other words, FDA is modernizing the nouns before the science fully modernizes the workflow. That is modest regulatory housekeeping, but housekeeping can matter when the old labels quietly shape the available choices. Read the direct final rule and its effective-date conditions in the Federal Register (https://www.federalregister.gov/documents/2026/09/22/2026-19350/nonclinical-testing-terminology), along with the companion proposed rule (https://www.federalregister.gov/documents/2026/09/22/2026-19349/nonclinical-testing-terminology).